^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Pyk2 inhibitor

    Related drugs:
    Apply
    A Study of Avutometinib and Defactinib in People With Thyroid Cancer (NCT06007924)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/16/2023
    Primary completion :
    08/16/2027
    Completion :
    08/16/2027
    BRAF • ALK • RET • NF1 • NTRK
    |
    BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement
    |
    avutometinib (VS-6766) • defactinib (VS-6063)
    A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK) (NCT05512208)
    Phase 2
    University of Oklahoma
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/06/2023
    Primary completion :
    12/01/2027
    Completion :
    12/01/2029
    BRAF • NF1 • RAS
    |
    BRAF mutation • RAS mutation
    |
    avutometinib (VS-6766) • defactinib (VS-6063)
    Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP 203) (NCT05074810)
    Phase 1/2
    Verastem, Inc.
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    04/12/2022
    Primary completion :
    09/01/2025
    Completion :
    04/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • avutometinib (VS-6766) • defactinib (VS-6063)
    Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE) (NCT06194929)
    Phase 1/2
    University of Utah
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    03/07/2024
    Primary completion :
    01/15/2028
    Completion :
    01/15/2030
    NF1 • RAS
    |
    BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation
    |
    Braftovi (encorafenib) • avutometinib (VS-6766) • defactinib (VS-6063)
    5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (NCT06630260)
    Phase 1/2
    Institute of Cancer Research, United Kingdom
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    11/15/2024
    Primary completion :
    09/30/2029
    Completion :
    09/30/2030
    BRAF
    |
    temozolomide • avutometinib (VS-6766) • defactinib (VS-6063)
    Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer (NCT02695550)
    Phase 1
    Centaurus Biopharma Co., Ltd.
    Unknown status
    Last update posted :
    03/09/2017
    Initiation :
    03/01/2016
    Primary completion :
    03/01/2018
    Completion :
    03/01/2018
    ALK
    |
    ALK positive • ALK rearrangement
    |
    Xalkori (crizotinib) • conteltinib (SY-707)